Join us in our mission to improve the lives of those with autoimmune hepatitis (AIH).

The PORTOLA Phase 2a clinical trial is enrolling people living with autoimmune hepatitis.

Zetomipzomib (KZR-616) is an investigational product and has not been approved for commercial use in the United States or any other country for any indication.